I think, you know, belzutifan can be used as a monotherapy, but also in combination. And in the setting of, you know, ASCO-GU 2026, it’s important to point out the presentation that will be done tomorrow around LITESPARK-011, which is a combination of belzutifan with lenvatinib versus cabozantinib in patients who were previously treated with immune checkpoint inhibitors...
I think, you know, belzutifan can be used as a monotherapy, but also in combination. And in the setting of, you know, ASCO-GU 2026, it’s important to point out the presentation that will be done tomorrow around LITESPARK-011, which is a combination of belzutifan with lenvatinib versus cabozantinib in patients who were previously treated with immune checkpoint inhibitors. And I think the data from this aspect will help better shed light on the role of belzutifan, especially belzutifan-based combination, along with TKIs, and better understanding where does this fit within the treatment algorithm.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
